CRISPR/Cas9 technology introduced a single nucleotide mutation of G to T at nucleotide 296 in which cysteine at amino acid 99 within the PHD domain is replaced with a phenylalanine (C99F). This is a mutation found in Borjeson-Forssman-Lehmann Syndrome patients.